Precision BioSciences (DTIL) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Ocugen (OCGN) over the past year, gaining 48.0% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -97.2% for DTIL. Precision BioSciences is the larger company by market cap ($282.5 million vs $260.6 million), about 1.1 times the size, while Ocugen is growing revenue faster (+8.8% vs -50.1%).
Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -1537.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | OCGN |
|---|---|---|
| Share price | $7.40 | $0.7679 |
| Market cap | $282.46M | $260.55M |
| 1-day change | +7.09% | +4.79% |
| YTD return | +77.88% | -43.12% |
| 1-year return | +48.00% | -33.80% |
| 5-year return | -97.23% | -88.09% |
| P/E ratio (TTM) | 29.60 | — |
| EPS (TTM) | $0.25 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $34.26M | $4.41M |
| Revenue growth (YoY) | -50.12% | +8.83% |
| Net income (latest FY) | $-45.72M | $-67.85M |
| Operating margin | -152.19% | -1425.70% |
| Net margin | -133.45% | -1537.41% |
| 52-week high | $11.29 | $2.73 |
| 52-week low | $3.53 | $0.691 |
| Distance from 52-week high | -34.46% | -71.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +297.30% | +1484.84% |
| Average volume | 319.79K | 7.34M |
| Shares outstanding | 38.17M | 339.31M |
| Employees | 69 | 116 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed OCGN by 81.8 percentage points over the past year.
- Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
- Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -50.12%).
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
DTIL vs OCGN FAQ
Which is bigger, Precision BioSciences or Ocugen?
Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $260.55M for Ocugen (OCGN).
Which stock has performed better over the past year, DTIL or OCGN?
DTIL returned +48.00% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.